



Corrigendum: Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics

OPEN ACCESS

Edited and reviewed by:

Aixin Yan,
The University of Hong Kong,
Hong Kong

*Correspondence:

Martti Vaara
martti.vaara@northernantibiotics.com

†ORCID:

Martti Vaara
orcid.org/0000-0002-7971-0560

Specialty section:

This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology

Received: 06 August 2019

Accepted: 18 September 2019

Published: 01 October 2019

Citation:

Vaara M (2019) Corrigendum:
Polymyxins and Their Potential Next
Generation as Therapeutic Antibiotics.
Front. Microbiol. 10:2275.
doi: 10.3389/fmicb.2019.02275

Martti Vaara^{1,2*†}

¹ Northern Antibiotics Ltd., Espoo, Finland, ² Department of Bacteriology and Immunology, Helsinki University Medical School, Helsinki, Finland

Keywords: polymyxin B, colistin, extremely resistant (XDR), Gram-negative bacteria, improved polymyxins

A Corrigendum on

Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics

by Vaara M. (2019). *Front. Microbiol.* 10:1689. doi: 10.3389/fmicb.2019.01689

In the original article, there was a mistake in **Table 1** as published. The structure of SPR206 was partially incorrect. In the correct structure, R(FA) is (3S)-4-amino-3-(3-chlorophenyl)butanoyl, R1 is absent, and R3 is Dap⁺. The corrected **Table 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2019 Vaara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

TABLE 1 | The structures of polymyxin B, colistin, and the novel polymyxin derivatives that display improved efficacy in animal infection models (compounds 4-10)^{a,b}.

Compound	R (FA)	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
1 Polymyxin B (PMB)	Methyloctanoyl/methylheptanoyl	-Dab ⁺	-Thr	-Dab ⁺	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Dab ⁺	-Dab ⁺	-Thr]
2 Colistin (polymyxin E)	Methyloctanoyl/methylheptanoyl	-Dab ⁺	-Thr	-Dab ⁺	-cy[Dab	-Dab ⁺	-DLeu	-Leu	-Dab ⁺	-Dab ⁺	-Thr]
3 CB-182,804	2-chloro-phenylamino-carbonyl	-Dab ⁺	-Thr	-Dab ⁺	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Dab ⁺	-Dab ⁺	-Thr]
4 FADDI-002	Octanoyl	-Dab ⁺	-Thr	-Dab ⁺	-cy[Dab	-Dab ⁺	-DPhe	-Ada	-Dab ⁺	-Dab ⁺	-Thr]
5 FADDI-287	Octanoyl	-Dab ⁺	-Thr	-Dap ⁺	-cy[Dab	-Dab ⁺	-DLeu	-Abu	-Dab ⁺	-Dab ⁺	-Thr]
6 CA824	(S)-1-(2-methylpropyl)-piperazine-2-carbonyl ⁺	-	-Thr	-Dab ⁺	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Dab ⁺	-Dab ⁺	-Thr]
7 SPR206	(3S)-4-amino-3-(3-chlorophenyl)butanoyl	-	-Thr	-Dap ⁺	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Dab ⁺	-Dab ⁺	-Thr]
8 MicuRx-12	3-(2,2-dimethyl-butanoxyloxy)-propanoyl (ester bond)	-Dab ⁺	-Thr	-Dab ⁺	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Dab ⁺	-Dab ⁺	-Thr]
9 NAB739	Octanoyl	-	-Thr	-DSer	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Dab ⁺	-Dab ⁺	-Thr]
10 NAB815	Octanoyl	-Dab ⁺	-Thr	-DThr	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Abu	-Dab ⁺	-Thr]
11 SPR741 (NAB741)	Acetyl	-	-Thr	-DSer	-cy[Dab	-Dab ⁺	-DPhe	-Leu	-Dab ⁺	-Dab ⁺	-Thr]

The structure of one discontinued derivative (compound 3) as well as that of the potentiator compound SPR741 (NAB741) are also shown. ^aAmino acyl residues that differ from those in polymyxin B are boxed. ^bAbu, aminobutyryl; Ada, aminodecanoyl; Dap, diaminopropionyl; cy, cyclic portion indicated with brackets; Dab, diaminobutyryl; FA, fatty acyl.